Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (1238)	1/2/1999 10:35:00 AM
From: Emec	Read Replies (1) \| Respond to of 1510

gent End-of-Year Update by: Country_Doctor 6211 of 6226 (this message is a repost due to YAHOO inefficiency) When IMNR recently announced the RA data, they stated that they are looking for a corporate partner for the RA product, IR501. There may be some confusion and misunderstanding regarding this point and I want to set the record straight: The data have already been presented to the various pharmaceutical companies, and they are now doing their homework. None of them wants to be out bid and IMNR is choosing with whom to strike the deal. Now, let's use some logic and simple reasoning. In the next 10 days or so, AGPH will make a $10 million milestone payment, bringing their investment in IMNR to $25million. This, I feel, represents the "point of no return". AGPH feels confident they can shepherd Remune through the FDA regulatory process before the end of 1999. David Saks, senior Biotech Analyst at Gruntal believes Remune could be commercially available by end of year 1999. Consider this scenario: AGPH, Glaxo & Merck all appreciate the value of Remune, having seen their products used in conjunction with Remune in the Valentine study. DuPont is now focusing on life sciences and biotech and they too have entered the HIV arena. Hoffman-Laroche is providing foreign distribution for Viracept and they will eventually do the same for Remune. All of these companies are contenders for a high level agreement or buyout of IMNR. AGPH could potentially find themselves in the unwanted position of being partners with the likes of Glaxo, Merck or DuPont and owning only 50% of the Remune profits. Quite conceivably, AGPH will find it more profitable for them to merge with, or buy out IMNR, thereby receiving all of the Remune profits. They won't allow themselves to be outbid. The upcoming $10 million milestone payment represents more than one type of milestone. The recent press release was somewhat "underwhelming", but those who follow IMNR know that PR has never been of major importance to them. Their credo has been, "Let the science and data speak for themselves." I believe it was the late Jonas Salk, MD, the founder of IMNR, who frequently stated this. Finally, if you think that the company is closed for the holidays, you're wrong; remember, "Money never sleeps". Happy New Year to all! CD